Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.75 USD | +1.35% | -1.32% | +4.17% |
05-15 | NeuroMetrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 5.597 | 4.206 | 11.96 | 33.51 | 11.56 | 3.866 |
Enterprise Value (EV) 1 | -1.183 | 2.585 | 7.794 | 11.47 | -9.286 | -13.89 |
P/E ratio | 380 x | -1.1 x | -4.55 x | -11.2 x | -2.41 x | -0.57 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.35 x | 0.45 x | 1.62 x | 4.06 x | 1.4 x | 0.66 x |
EV / Revenue | -0.07 x | 0.28 x | 1.06 x | 1.39 x | -1.12 x | -2.35 x |
EV / EBITDA | 0.1 x | -0.29 x | -4.71 x | -5.2 x | 1.98 x | 1.96 x |
EV / FCF | 0.21 x | -0.43 x | -6.88 x | -10.6 x | 2.36 x | 3.74 x |
FCF Yield | 471% | -231% | -14.5% | -9.46% | 42.3% | 26.7% |
Price to Book | 0.92 x | 2.38 x | 2.28 x | 1.44 x | 0.5 x | 0.27 x |
Nbr of stocks (in thousands) | 92.1 | 122 | 473 | 834 | 970 | 1,074 |
Reference price 2 | 60.80 | 34.40 | 25.28 | 40.16 | 11.92 | 3.600 |
Announcement Date | 1/24/19 | 1/28/20 | 1/29/21 | 1/28/22 | 3/22/23 | 3/1/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 16.09 | 9.273 | 7.378 | 8.253 | 8.256 | 5.901 |
EBITDA 1 | -12.12 | -8.79 | -1.655 | -2.208 | -4.692 | -7.096 |
EBIT 1 | -12.29 | -8.914 | -1.745 | -2.285 | -4.742 | -7.152 |
Operating Margin | -76.39% | -96.13% | -23.65% | -27.68% | -57.43% | -121.18% |
Earnings before Tax (EBT) 1 | 0.0236 | -3.773 | -2.092 | -2.281 | -4.417 | -6.529 |
Net income 1 | 0.0236 | -3.773 | -2.092 | -2.281 | -4.417 | -6.529 |
Net margin | 0.15% | -40.69% | -28.36% | -27.64% | -53.5% | -110.64% |
EPS 2 | 0.1600 | -31.20 | -5.552 | -3.571 | -4.955 | -6.270 |
Free Cash Flow 1 | -5.567 | -5.961 | -1.133 | -1.086 | -3.931 | -3.714 |
FCF margin | -34.6% | -64.29% | -15.36% | -13.15% | -47.61% | -62.93% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 1/24/19 | 1/28/20 | 1/29/21 | 1/28/22 | 3/22/23 | 3/1/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 6.78 | 1.62 | 4.17 | 22 | 20.8 | 17.8 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -5.57 | -5.96 | -1.13 | -1.09 | -3.93 | -3.71 |
ROE (net income / shareholders' equity) | 0.42% | -87.5% | -53.8% | -16% | -19% | -30.1% |
ROA (Net income/ Total Assets) | -70.8% | -53.4% | -14.6% | -8.68% | -12% | -19.4% |
Assets 1 | -0.0334 | 7.072 | 14.28 | 26.27 | 36.93 | 33.67 |
Book Value Per Share 2 | 66.10 | 14.50 | 11.10 | 27.80 | 24.00 | 13.20 |
Cash Flow per Share 2 | 73.50 | 17.90 | 11.00 | 27.00 | 4.370 | 1.140 |
Capex 1 | 0.14 | 0.05 | - | 0.13 | 0.02 | 0.18 |
Capex / Sales | 0.89% | 0.52% | - | 1.6% | 0.28% | 3.11% |
Announcement Date | 1/24/19 | 1/28/20 | 1/29/21 | 1/28/22 | 3/22/23 | 3/1/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+4.17% | 7.44M | |
-4.60% | 182B | |
-4.13% | 103B | |
-5.30% | 66.94B | |
+8.97% | 46.73B | |
-8.48% | 45.14B | |
+5.82% | 41.57B | |
+17.48% | 30.48B | |
+14.00% | 24.26B | |
-6.12% | 23.58B |
- Stock Market
- Equities
- NURO Stock
- Financials NeuroMetrix, Inc.